Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies

Lucila N. Kerbauy, Nancy D. Marin, Mecit Kaplan, Pinaki P. Banerjee, Melissa M. Berrien-Elliott, Michelle Becker-Hapak, Rafet Basar, Mark Foster, Luciana Garcia Melo, Carly C. Neal, Ethan McClain, May Daher, Ana Karen Nunez Cortes, Sweta Desai, Francesca Wei Inng Lim, Mayela Carolina Mendt, Timothy Schappe, Li Li, Hila Shaim, Mayra ShanleyEmily L. Ensley, Nadima Uprety, Pamela Wong, Enli Liu, Sonny O. Ang, Rong Cai, Vandana Nandivada, Vakul Mohanty, Qi Miao, Yifei Shen, Natalia Baran, Natalie W. Fowlkes, Ken Chen, Luis Muniz-Feliciano, Richard E. Champlin, Yago L. Nieto, Joachim Koch, Martin Treder, Wolfgang Fischer, Oswaldo Keith Okamoto, Elizabeth J. Shpall, Todd A. Fehniger, Katayoun Rezvani

Research output: Contribution to journal › Article › peer-review

68 Scopus citations

Fingerprint

Dive into the research topics of 'Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated blood and cord blood–derived NK cells facilitates CAR-like responses against CD30+ malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences